Recent Updates
Recently added Catalysts
ONC Positive Sentiment Score: 70/100

BeOne Medicines to Present at Upcoming Investor Conferences

Key Takeaway: BeOne Medicines Ltd. announced its participation in four upcoming investor conferences, where it will engage in fireside chats. The company focuses on developing innovative cancer treatments and has a diverse pipeline aimed at hematology and solid tumors. Live webcasts of the events will be available on their website, along with archived replays.

Market Sentiment Analysis

POSITIVE FACTORS

  • BeOne Medicines is actively engaging with investors through multiple conferences.
  • The company is focused on innovative cancer treatments and has a diverse pipeline.
  • BeOne has a global team dedicated to expediting drug development.

Full Press Release Details

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at four upcoming investor conferences:
Live webcasts of these events can be accessed from the investors section of the Company’s website athttps://ir.beonemedicines.com. Archived replays will be available on the Company’s website.

About BeOne Medicines

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.
To learn more about BeOne, please visitwww.beonemedicines.comand follow us onLinkedIn,X,FacebookandInstagram.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne’s plans, commitments, aspirations and goals related to BeOne’s medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled “Risk Factors” in BeOne’s most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”) as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the SEC. All information in this press release is as of the date hereof, and BeOne undertakes no duty to update such information unless required by law.

Frequently Asked Questions

What is BeOne Medicines participating in?

BeOne Medicines is participating in four upcoming investor conferences.

Where can I access the live webcasts?

Live webcasts can be accessed from the investors section of BeOne's website.

What is BeOne Medicines focused on?

BeOne Medicines focuses on discovering and developing innovative cancer treatments.

What types of tumors does BeOne target?

BeOne targets both hematology and solid tumors in its treatment portfolio.

Last updated: Feb 17, 2026